FDA Biological Response Modifiers Advisory Committee
Agency's newest advisory committee will hold its first meeting July 30-31. The panel was formed to help with FDA reviews of cytokines and other biologicals seeking approval for use in treating cancer. The meeting's agenda has not been released, but reportedly, the committee's first reviews could involve GM-CSF and G-CSF. PLAs for GM-CSF products were filed earlier this year by Immunex and Schering-Plough. Amgen submitted a PLA for G-CSF in December.
You may also be interested in...
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Execs On The Move: Medical Microinstruments Gets New CEO; Changes At iRhythm; Aethlon Makes A Promotion
Corindus Vascular Robotics CEO made a lateral move to Medical Microinstruments; iRhythm hires a new CEO, while the former CEO stays on as a director; Aethlon promotes a director to chief business officer; and more.